论文部分内容阅读
目的探讨厄贝沙坦联合氨氯地平治疗中重度高血压的有效性和安全性。方法选择2008年1月—2010年12月中重度高血压患者102例,随机分成A、B、C三组各30、34、48例,A组给予厄贝沙坦治疗,B组给予氨氯地平治疗,C组给予厄贝沙坦联合氨氯地平治疗。结果治疗后C组与A、B组血压比较差异有统计学意义(P﹤0.05)。A、B、C三组总有效率分别为66.7%、67.6%、91.7%,A、B组总有效率比较差异无统计学意义(P>0.05),C组与A、B组总有效率比较差异均有统计学意义(均P>0.05)。A组发生不良反应6例,B组发生不良反应9例,C组发生不良反应4例。结论厄贝沙坦联合氨氯地平治疗中重度高血压有效、安全、耐受性好。
Objective To investigate the efficacy and safety of irbesartan and amlodipine in the treatment of moderate-severe hypertension. Methods From January 2008 to December 2010, 102 patients with moderate-to-severe hypertension were randomly divided into A, B, C three groups of 30,34,48 cases, A group treated with irbesartan, B group given amlodichloride Level treatment, group C given irbesartan combined with amlodipine treatment. Results After treatment, there was significant difference in blood pressure between group C and group A and group B (P <0.05). The total effective rates of A, B and C groups were 66.7%, 67.6% and 91.7%, respectively. There was no significant difference in total effective rate between A and B groups (P> 0.05) The differences were statistically significant (all P> 0.05). There were 6 adverse reactions in group A, 9 in group B and 4 in group C. Conclusion Irbesartan combined with amlodipine in the treatment of moderate to severe hypertension is effective, safe and well tolerated.